Trial record 1 of 9 for:
curevac | Covid19
A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04652102 |
|
Recruitment Status :
Completed
First Posted : December 3, 2020
Last Update Posted : June 22, 2022
|
Sponsor:
CureVac
Information provided by (Responsible Party):
CureVac
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.
The primary objective of the open-label phase of this trial is to evaluate safety in all participants ≥ 18 years of age remaining in the trial after unblinding.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Covid19 SARS-CoV-2 | Biological: CVnCoV Biological: Placebo Biological: Authorized/licensed vaccines for preventing COVID-19 (AV) | Phase 2 Phase 3 |
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 39693 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | The randomized observer-blinded phases of this study are participant and investigator blinded. This is followed by an open-label phase. |
| Primary Purpose: | Prevention |
| Official Title: | COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older |
| Actual Study Start Date : | December 14, 2020 |
| Actual Primary Completion Date : | June 3, 2022 |
| Actual Study Completion Date : | June 3, 2022 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Randomized Observer-blinded Phase 2b: CVnCoV vaccine
Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
|
Biological: CVnCoV
Intramuscular (IM) injection.
Other Name: CV07050101 |
|
Placebo Comparator: Randomized Observer-blinded Phase 2b: Placebo
Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
|
Biological: Placebo
Intramuscular (IM) injection. |
|
Experimental: Randomized Observer-blinded Phase 3: CVnCoV vaccine
Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
|
Biological: CVnCoV
Intramuscular (IM) injection.
Other Name: CV07050101 |
|
Placebo Comparator: Randomized Observer-blinded Phase 3: Placebo
Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
|
Biological: Placebo
Intramuscular (IM) injection. |
|
Experimental: Open-label Phase
After unblinding, the trial will shift from a randomized observer-blinded to an open-label design, and the following cohorts will be defined: Cohort A: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to receive an authorized/licensed vaccine for preventing COVID-19 (AV) as standard of care through their national vaccination program. Cohort B: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to remain in the trial without receiving any AV. Participants on the placebo arm will be withdrawn. |
Biological: Authorized/licensed vaccines for preventing COVID-19 (AV)
Intramuscular (IM) injection will be received as standard of care (SoC) outside the study. |
Primary Outcome Measures :
- Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience one or more medically-attended adverse events (AEs) [ Time Frame: Day 29 to Day 211 ]
- Intensity grading of medically-attended adverse events (AEs) as per adapted Food and Drug Administration (FDA) classification [ Time Frame: Day 29 to Day 211 ]The adapted FDA classification will grade AEs on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Number of participants who experience one or more treatment-related medically-attended adverse events (AEs) [ Time Frame: Day 29 to Day 211 ]
- Number of participants who experience one or more serious adverse events (SAEs) [ Time Frame: Day 1 to Day 393 ]
- Intensity grading of serious adverse events (SAEs) as per adapted FDA classification [ Time Frame: Day 1 to Day 393 ]The adapted FDA classification will grade SAEs on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Number of participants who experience one or more treatment-related serious adverse events (SAEs) [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience one or more adverse events of special interest (AESI) [ Time Frame: Day 1 to Day 393 ]
- Intensity grading of adverse events of special interest (AESI) as per adapted FDA classification [ Time Frame: Day 1 to Day 393 ]The adapted FDA classification will grade AESI on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Number of participants who experience one or more treatment-related adverse events of special interest (AESI) [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience a fatal serious adverse event (SAE) [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience an adverse event (AE) leading to authorized/licensed vaccines withdrawal or trial discontinuation after first dose with an authorized/licensed vaccine for preventing COVID-19 (AV) administered [ Time Frame: Day 1 to Day 393 ]Measured in the open-label phase, Cohort A only.
- Phase 2b participants only: Number of participants who experience one or more solicited local adverse events (AEs) [ Time Frame: 7 days after vaccination ]
- Phase 2b participants only: Intensity grading of solicited local adverse events (AEs) as per adapted FDA classification [ Time Frame: 7 days after vaccination ]The adapted FDA classification will grade AEs on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Phase 2b participants only: Duration of solicited local adverse events (AEs) [ Time Frame: 7 days after vaccination ]
- Phase 2b participants only: Number of participants who experience one or more solicited systemic adverse events (AE) [ Time Frame: 7 days after vaccination ]
- Phase 2b participants only: Intensity grading of solicited systemic adverse events (AEs) as per adapted FDA classification [ Time Frame: 7 days after vaccination ]The adapted FDA classification will grade AEs on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Phase 2b participants only: Duration of solicited systemic adverse events (AEs) [ Time Frame: 7 days after vaccination ]
- Phase 2b participants only: Number of participants who experience one or more unsolicited adverse events (AEs) [ Time Frame: 28 days after vaccination ]
- Phase 2b participants only: Intensity grading of unsolicited adverse events (AEs) as per adapted FDA classification [ Time Frame: 28 days after vaccination ]The adapted FDA classification will grade AEs on a grade of 0 to 3. Higher grades indicate a worse outcome.
- Phase 2b participants only: Number of participants who experience one or more treatment-related unsolicited adverse events (AEs) [ Time Frame: 28 days after vaccination ]
- Number of participants who experience one or more adverse events (AEs) leading to vaccine withdrawal or trial discontinuation [ Time Frame: Day 1 to Day 393 ]
Secondary Outcome Measures :
- Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} moderate to severe case of COVID-19 [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} severe case of COVID-19 [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity due to infection with "wild type" and "UK" SARS-CoV-2 strains [ Time Frame: Day 1 to Day 393 ]Measured in SARS-CoV-2 naïve participants.
- Number of participants aged ≥ 61 who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} SARS-CoV-2 infection, with or without symptoms [ Time Frame: Day 1 to Day 393 ]
- Burden of disease (BoD) based on first episodes of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} cases of COVID-19 [ Time Frame: Day 1 to Day 393 ]
- Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity with symptom onset at any time after the first study vaccination [ Time Frame: Post vaccination on Day 1 up to Day 393 ]
- Number of participants with serum antibodies to SARS-CoV-2 spike (S) protein [ Time Frame: Days 1, 29, 43, 120 and 211 ]S protein will be measured by enzyme-linked immunosorbent assay (ELISA).
- Number of participants who experience seroconversion to SARS-CoV-2 spike (S) protein [ Time Frame: Days 1, 29, 43, 120 and 211 ]S protein will be measured by enzyme-linked immunosorbent assay (ELISA). Seroconversion is defined as detectable SARS-CoV-2 S protein antibodies in the serum of participants who tested seronegative on Day 1.
- Number of participants with serum vital neutralizing antibodies to SARS-CoV-2 virus [ Time Frame: Days 1, 29, 43, 120 and 211 ]Serum vital neutralizing antibodies to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay.
- Number of participants who experience seroconversion to SARS-CoV-2 virus [ Time Frame: Days 1, 29, 43, 120 and 211 ]Seroconversion to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay. Seroconversion is defined as detectable SARS-CoV-2 viral neutralizing antibodies in the serum of participants who tested seronegative on Day 1.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female participants 18 years of age or older.
- Be willing and able to provide written informed consent prior to initiation of any trial procedures.
- Expected compliance with protocol procedures and availability for clinical follow-up through the last planned visit.
- Females of non-childbearing potential defined as follows: surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or postmenopausal {defined as amenorrhea for ≥12 consecutive months prior to screening (Day 1) without an alternative medical cause}. A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status.
- Females of childbearing potential: negative pregnancy test (human chorionic gonadotropin [hCG]) within 24 hours prior to each trial vaccination on Day 1 and Day 29.
-
Females of childbearing potential must use highly effective methods of birth control from 2 weeks before the first administration of the trial vaccine until 3 months following the last administration. The following methods of birth control are considered highly effective when used consistently and correctly:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal);
- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable);
- Intrauterine devices;
- Intrauterine hormone-releasing systems;
- Bilateral tubal ligation;
- Vasectomized or infertile partner;
- Sexual abstinence
- {periodic abstinence (e.g., calendar, ovulation, symptothermal and post-ovulation methods) and withdrawal are not acceptable}.
Exclusion Criteria:
- History of virologically-confirmed COVID-19 illness.
- For females: pregnancy or lactation.
- Use of any investigational or non-registered product (vaccine or drug) within 28 days preceding the administration of trial vaccine or planned use during the trial.
- Receipt of any licensed vaccines within 28 days (for live vaccines) or 14 days (for inactivated or any other vaccines) prior to administration of the first trial vaccine.
- Prior administration of any investigational SARS-CoV-2 vaccine or another coronavirus (SARS-CoV, Middle East Respiratory Syndrome-CoV) vaccine or planned used during the trial.
- Any treatment with immunosuppressants or other immune-modifying drugs (including but not limited to anabolic steroids, corticosteroids, biologicals and methotrexate) for > 14 days total within 6 months preceding the administration of trial vaccine or planned use during the trial. For corticosteroid use, this means prednisone or equivalent, 0.5 mg/kg/day for 14 days or more. The use of inhaled, topical, or localized injections of corticosteroids (e.g., for joint pain/inflammation) is permitted.
- Any medically diagnosed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination including known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); current diagnosis of or treatment for cancer including leukemia, lymphoma, Hodgkin disease, multiple myeloma or generalized malignancy; chronic renal failure or nephrotic syndrome; and receipt of an organ or bone marrow transplant.
- History of angioedema (hereditary or idiopathic) or history of any anaphylactic reaction.
- History of potential immune-mediated disease (pIMD).
- History of allergy to any component of CVnCoV.
- Administration of immunoglobulins or any blood products within 3 months prior to the administration of trial vaccine or planned receipt during the trial.
- Participants with a significant acute or chronic medical or psychiatric illness that, in the opinion of the Investigator, precludes trial participation (e.g., may increase the risk of trial participation, render the participant unable to meet the requirements of the trial, or may interfere with the participant's trial evaluations). These include severe and/or uncontrolled cardiovascular disease, gastrointestinal disease, liver disease, renal disease, respiratory disease, endocrine disorder, and neurological and psychiatric illnesses. However, those with controlled and stable cases can be included in the trial.
- Participants with impaired coagulation or any bleeding disorder in whom an IM injection or a blood draw is contraindicated.
- Foreseeable non-compliance with the trial procedure as judged by the Investigator.
Roll-over Criteria for the Open-label Phase:
- Participants must have received at least 1 dose of CVnCoV during the randomized observer blinded phase.
- Participants must provide additional written informed consent to be eligible for the open label phase.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04652102
Locations
Show 46 study locations
Sponsors and Collaborators
CureVac
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | CureVac |
| ClinicalTrials.gov Identifier: | NCT04652102 |
| Other Study ID Numbers: |
CV-NCOV-004 2020-003998-22 ( EudraCT Number ) |
| First Posted: | December 3, 2020 Key Record Dates |
| Last Update Posted: | June 22, 2022 |
| Last Verified: | June 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by CureVac:
|
Vaccine |
Additional relevant MeSH terms:
|
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |